OBJECTIVES: To assess the accuracy of the Microlife 3AS1-2 blood pressure device in pregnancy and pre-eclampsia in a low-resource setting. METHODS: Prospective validation according to the British Hypertension Society protocol. A total of 45 pregnant women were recruited from Kimberley Hospital (South Africa), of whom 15 had pre-eclampsia. RESULTS: The Microlife 3AS1-2 device achieved an overall B/A grade in pregnancy (including pre-eclampsia), passing the British Hypertension Society protocol requirements and achieving the International Organization for Standardization standard with a mean difference and SD of -3.8 ± 7.3 and -1.5 ± 6.2 mmHg for systolic and diastolic pressures, respectively. CONCLUSION: The Microlife 3AS1-2 device can be recommended for use in pregnancy, including pre-eclampsia. In addition, it fulfils the requirements stipulated by the WHO for an automated blood pressure device suitable for use in a low-resource setting. This makes it the ideal device for antenatal clinics and primary healthcare facilities in low-income and middle-income countries.
OBJECTIVES: To assess the accuracy of the Microlife 3AS1-2 blood pressure device in pregnancy and pre-eclampsia in a low-resource setting. METHODS: Prospective validation according to the British Hypertension Society protocol. A total of 45 pregnant women were recruited from Kimberley Hospital (South Africa), of whom 15 had pre-eclampsia. RESULTS: The Microlife 3AS1-2 device achieved an overall B/A grade in pregnancy (including pre-eclampsia), passing the British Hypertension Society protocol requirements and achieving the International Organization for Standardization standard with a mean difference and SD of -3.8 ± 7.3 and -1.5 ± 6.2 mmHg for systolic and diastolic pressures, respectively. CONCLUSION: The Microlife 3AS1-2 device can be recommended for use in pregnancy, including pre-eclampsia. In addition, it fulfils the requirements stipulated by the WHO for an automated blood pressure device suitable for use in a low-resource setting. This makes it the ideal device for antenatal clinics and primary healthcare facilities in low-income and middle-income countries.
Authors: Natalie A Bello; Jonathan J Woolley; Kirsten Lawrence Cleary; Louise Falzon; Bruce S Alpert; Suzanne Oparil; Gary Cutter; Ronald Wapner; Paul Muntner; Alan T Tita; Daichi Shimbo Journal: Hypertension Date: 2017-12-11 Impact factor: 10.190
Authors: Lilian Toledo-Jaldin; Sheana Bull; Stephen Contag; Carlos Escudero; Patricio Gutierrez; Alexandra Heath; James M Roberts; Jean Scandlyn; Colleen G Julian; Lorna G Moore Journal: Pregnancy Hypertens Date: 2019-03-14 Impact factor: 2.899
Authors: Alison M El Ayadi; Hannah L Nathan; Paul T Seed; Elizabeth A Butrick; Natasha L Hezelgrave; Andrew H Shennan; Suellen Miller Journal: PLoS One Date: 2016-02-22 Impact factor: 3.240
Authors: Hannah L Nathan; Helena Boene; Khatia Munguambe; Esperança Sevene; David Akeju; Olalekan O Adetoro; Umesh Charanthimath; Mrutyunjaya B Bellad; Annemarie de Greeff; John Anthony; David R Hall; Wilhelm Steyn; Marianne Vidler; Peter von Dadelszen; Lucy C Chappell; Jane Sandall; Andrew H Shennan Journal: Reprod Health Date: 2018-01-05 Impact factor: 3.223
Authors: Sumedha Sharma; Olalekan O Adetoro; Marianne Vidler; Sharla Drebit; Beth A Payne; David O Akeju; Akinmade Adepoju; Ebunoluwa Jaiyesimi; John Sotunsa; Zulfiqar A Bhutta; Laura A Magee; Peter von Dadelszen; Olukayode Dada Journal: BMC Health Serv Res Date: 2017-03-28 Impact factor: 2.655
Authors: Laura A Magee; Jeffrey Bone; Salwa Banoo Owasil; Joel Singer; Terry Lee; Mrutunjaya B Bellad; Shivaprasad S Goudar; Alexander G Logan; Salésio E Macuacua; Ashalata A Mallapur; Hannah L Nathan; Rahat N Qureshi; Esperança Sevene; Andrew H Shennan; Anifa Valá; Marianne Vidler; Zulfiqar A Bhutta; Peter von Dadelszen Journal: Hypertension Date: 2021-03-29 Impact factor: 10.190